Skip to content

Platform
- Overview
- Publications
Pipeline
About
Investors
Careers
Contact

Platform
- Overview
- Publications
Pipeline
About
Investors
Careers
Contact

Platform:
Publications

man working - Alto publications hero

Leveraging clinical and biological insights to drive innovation in psychiatry

See our publications, presentations, and more to discover the revolutionary potential of our precision approach.

Choose Resource Type
Choose Focus Area
Search Resources

Found 57 Results

June 26, 2017

The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects

October 21, 2016

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

February 26, 2016

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months

June 18, 2014

Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch

December 16, 2013

The mechanism, efficacy, and tolerability profile of agomelatine

August 29, 2012

The Role of Phosphodiesterases in Schizophrenia

August 9, 2010

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

«...5 6 789 »

650 Castro Street, Suite 450
Mountain View, CA 94041

Company

About
Leadership
Careers
Contact

Science

Platform
Publications
Pipeline

Investors

Overview
News
Events & Presentations
Stock Info
SEC Filings
Corporate Governance
Resources

Privacy Policy
Terms of Use
Accessibility
Cookie Policy

© 2025 Alto Neuroscience Inc. All rights reserved.

Scroll to Top